Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer

1. Muñoz, A.
2. Pericay, C.
3. García-Girón, C.
4. Alonso, V.
5. Dueñas, R.
6. Cirera, L.
7. Rivera, F.
8. Falcó, E.
9. Bustos, I.A.
10. Salud, A.